Is he still on immu payroll?
http://www.pegsummit.com/
4:50 Trop-2 as a Broad Solid Cancer Target for Antibody-Drug Conjugates
 David Goldenberg, ScD, MD, Founder and Former CSO, Immunomedics, Inc.
Trop-2 is a transmembrane glycoprotein that transduce cytoplasmic calcium signal, activates MAPK/ERK pathway, and affects cell-cell adhesion. Using a proprietary linker technology to site-specifically conjugate an average of 7.6 molecules of SN-38 (the active metabolite of irinotecan, which inhibits nuclear topoisomerase I) per humanized IgG, my group demonstrated effective and selective tumor inhibition in vitro and in xenograft solid tumor models, as well as in phase 2 studies of ~500 patients with advanced, heavily-pretreated diverse solid cancers (e.g., breast, NSCLC, SCLC, urothelial).
Limitations of First-Generation ADCs in Solid Cancers
David Goldenberg, ScD, MD, Founder and Former CSO, Immunomedics, Inc.
Prospects for next-generation ADCs in solid cancersRole of antigen target, drug-antibody ratio, nature of drug, conjugation chemistry, drug resistance. |
